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Evaluation of Cu(I) binding to the E2 domain of
the amyloid precursor protein – a lesson in
quantification of metal binding to proteins via
ligand competition†
Tessa R. Young, a Anthony G. Wedda and Zhiguang Xiao *ab
The extracellular domain E2 of the amyloid precursor protein (APP) features a His-rich metal-binding
site (denoted as the M1 site). In conjunction with surrounding basic residues, the site participates in
interactions with components of the extracellular matrix including heparins, a class of negatively
charged polysaccharide molecules of varying length. This work studied the chemistry of Cu(I) binding to
APP E2 with the probe ligands Bcs, Bca, Fz and Fs. APP E2 forms a stable Cu(I)-mediated ternary
complex with each of these anionic ligands. The complex with Bca was selected for isolation
and characterization and was demonstrated, by native ESI-MS analysis, to have the stoichiometry
E2 :Cu(I) : Bca = 1 : 1 : 1. Formation of these ternary complexes is specific for the APP E2 domain and
requires Cu(I) coordination to the M1 site. Mutation of the M1 site was consistent with the His ligands
being part of the E2 ligand set. It is likely that interactions between the negatively charged probe ligands
and a positively charged patch on the surface of APP E2 are one aspect of the generation of the stable
ternary complexes. Their formation prevented meaningful quantification of the aﬃnity of Cu(I) binding to
the M1 site with these probe ligands. However, the ternary complexes are disrupted by heparin, allowing
reliable determination of a picomolar Cu(I) aﬃnity for the E2/heparin complex with the Fz or Bca probe
ligands. This is the first documented example of the formation of stable ternary complexes between a
Cu(I) binding protein and a probe ligand. The ready disruption of the complexes by heparin identified
clear ‘tell-tale’ signs for diagnosis of ternary complex formation and allowed a systematic review of
conditions and criteria for reliable determination of aﬃnities for metal binding via ligand competition.
This study also provides new insights into a potential correlation of APP functions regulated by copper
binding and heparin interaction.
Significance to metallomics
The APP E2 protein domain forms stable Cu(I)-mediated ternary complexes with several commonly used competing ligands which, however, are disrupted upon
addition of heparin, a physiological interacting partner of the APP. This provides new insights into the interactions of the APP with metals and heparin, which
may both be involved in mediating the physiological functions of APP in the human brain. In addition, this study also allows validation of several simple
control experiments which can be applied generally to confirm or disprove the presence of stable ternary complexes in metal-binding competition experiments.
Introduction
The aﬃnity for a metal ion M binding to a protein ligand P is
defined by the dissociation constant KD (eqn (1)).
MPÐMþ P KD ¼ ½M½P½MP (1)
The accurate determination of these aﬃnities provides a thermo-
dynamic rationale for metal speciation and reactivity in a
biological system.1–3 It contributes to an understanding of the
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maintenance of metal homeostasis in health and its disruption
in disease. However, direct determination of KD according to
eqn (1) can be difficult since the affinities of proteins for
transition metals are often high (KD o 107 M) and the ’free
metal ion’ concentrations [M] in the presence of excess protein
ligand are normally below reliable detection limits.1 Currently,
this difficulty is circumvented most effectively by employing a
competing ligand L of known affinity to impose the competition
equilibrium of eqn (2) for reliable quantification via eqn (3).1,4,5
MLn + P" MP + nL (2)
Kex ¼ ½MP½L
n
½MLn½P ¼
1
KDbn
(3)
Kex is the exchange equilibrium constant for eqn (2) and bn the
accumulated stepwise formation constant of the complex MLn
where n = 1 or 2 in most cases.
A criticism of this approach is the possible formation of a
ternary complex in which the metal ion M is coordinated
simultaneously to both ligand L and protein P. Short-lived
ternary complexes may facilitate transfer of the metal ion M
between ligand L and protein P but, provided that they are
transient, eqn (2) and (3) remain valid at equilibrium.
Copper is an essential but potentially toxic metal and must
be bound tightly at all times.6–8 Mishandling in cells is asso-
ciated with multiple disease states.9–11 Free Cu+ is unstable in
aqueous solution and so quantification of Cu(I) binding to
biomolecules is accomplished most reliably via the ligand
competition of eqn (2) and (3). The four bidentate ligands
ferrene S (Fs), ferrozine (Fz), bicinchoninic acid (Bca) and
bathocuproine disulfonate (Bcs) (Fig. 1) have been employed
widely for in vitro quantification of Cu(I) binding to bio-
molecules and been established as a set of complementary
probes with versatile in vitro applications.1,4,12–15 They each
bind Cu(I) to form a stable chromophoric 1 : 2 complex
[CuIL2]
3 with different log b2 values and distinct spectroscopic
fingerprints (see Table 1) that allow quantification of Cu(I)
affinities in the nanomolar to attomolar range.4,16 Stable
ternary complexes with protein ligands have not been reported.
We now report formation of stable ternary complexes
between Cu(I), the E2 domain of the amyloid precursor protein
(APP) and each of the above four ligands. These complexes are
disrupted in the presence of heparin, known to interact with
and bind to APP. This permitted reliable determination of a
picomolar Cu(I) aﬃnity for the E2/heparin complex, but not for
the APP E2 domain itself in the absence of heparin. Conse-
quently, this provided an opportunity to systematically review
the general conditions and criteria necessary for reliable quan-
tification of metal aﬃnity via ligand competition.
APP is a type I transmembrane glycoprotein with a large
extracellular domain (ectodomain) and a short amyloid intra-
cellular domain (AICD) (Fig. 2a).17,18 The former includes two
structured domains E1 (comprising subdomains D1 and D2)
and E2 that are linked by a flexible domain (AcD) composed
largely of aspartic and glutamic acid residues. A second flexible
linker, the juxtamembrane region (JMR) connects the extra-
cellular domain to the single transmembrane helix (TM). The
ectodomain interacts with components of the extracellular
matrix (ECM) while AICD interacts with many adaptor proteins
in the cytosol.19,20 Protease processing of APP generates amyloid
b peptides (Ab) of 36–43 amino acids which are critically involved
in Alzheimer’s disease as the main components of the amyloid
plaques found in the brains of Alzheimer patients.21
Interactions between copper ions and APP are a subject of
current interest as they may play a role in normal synaptic
function and in Alzheimer’s disease pathogenesis, as reviewed
recently.22,23 X-ray crystallographic studies have characterized
a Cu(I)/Cu(II) binding site in the APP D2 domain and a
Cu(II)-binding site in the APP E2 domain.24,25 The former site
features the imidazole side-chains of two His ligands (H147, H151)
with the nearby Tyr168 being claimed to be another possible metal
Fig. 1 Structures of the four Cu(I) probe ligands used in this work.
Table 1 Properties of chromophoric Cu(I) complexes [CuIL2]
3 a
Ligand (L) lmax (nm) emax (cm
1 M1) log b2
Fs 484 6700 13.7
Fz 470 4320 15.1
Bca 562 7900 17.2
358b 42 900b
Bcs 483 13 000 19.8
a Data quoted from ref. 4 and 16. b At low copper concentrations (o10 mM),
the [CuI(Bca)2]
3 complex was quantified by absorbance at 358 nm with
reference to copper-free ligand solution.
Fig. 2 (a) Schematic representation of the structure and subdomains of
APP-695; (b) crystal structure of APP D2 (pdb: 2FK2) with a close-up view
of the metal-binding site with Cu(I) or Cu(II) coordinated; (c) crystal
structure of APP E2 (pdb: 3UMK) with a close-up view of the metal-
binding M1 site with Cu(II) coordinated.
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ligand also (Fig. 2b).24 We have demonstrated that this site binds
Cu(I) withB0.1 nM aﬃnity and binds Cu(II) more weakly, by about
2 orders of magnitude.26 The Cu(II) site in APP E2 features four His
ligands (H313, H382, H432, H436) and was denoted the M1 metal-
binding site as it can also bind other divalent metal ions such as
Zn(II) and Cd(II) (Fig. 2c).25 We hypothesized that the same site may
be capable of coordinating Cu(I) as well. This could be of physio-
logical significance, considering the dynamic redox environment
in the synaptic cleft.27
APP is known to interact strongly with glycosaminoglycan
(GAG) ligands including heparins and heparan sulfate proteo-
glycans (HSPGs).28–30 The highest-affinity heparin binding site
is located within the E2 domain.31 Structural characterization
of E2/heparin complexes for homologous amyloid precursor-
like proteins 1 (APLP1) from human and from the worm
Caenorhabditis elegans have mapped the heparin binding sites
to a region involving the M1 site.32–35 A recent study showed
that Cu(II) binding to the M1 site in APP E2 enhances the
heparin binding affinity, as does Zn(II) to a lesser extent.36
Given the abundance of GAGs in the extracellular matrix, it is
likely that a high proportion of cell-surface APP is heparin-
bound.37 Consequently, the metal-binding properties of the
E2/heparin complex are of interest.
Experimental section
Materials and general methods
Reagents including buﬀers (Mops, ammonium acetate), ligands
(Fs, Fz, Bca, Bcs), metal salts (cupric sulfate and acetate),
reductants (NH2OH, ascorbic acid (Asc)) and heparin (H3393,
from porcine intestinal mucosa) were purchased from Sigma-
Aldrich and were all used as received. Concentrations of heparin
were estimated by mass, assuming an average molar mass of
19 kDa for the H3393 mixture.38 Cu(II) standards were prepared
by dissolving cupric salts in Milli-Q water. Their concentrations
were calibrated via reaction with excess ligand Bcs in Mops
buﬀer containing reductant NH2OH. Under such conditions, all
copper ions were converted quantitatively to the well-defined
chromophoric complex anion [CuI(Bcs)2]
3 (Table 1).39
Construction of expression plasmids
Genes encoding the APP E2 domain (residues 295–498 of
APP695) and a quadruple mutant of E2 (E2-qm; the four His
residues of the M1 site were converted to Ala: H313, 382, 432,
436A) were synthesized by Bio Basic Inc. (Canada) with DNA
genetic code optimized for expression in E. coli cells. These
genes included an N-terminal sequence coding for residues
‘MN’ to facilitate recombinant protein expression and N-terminal
acetylation in the E. coli host. The modified pET20b expression
vector (see Table S1, ESI†) included a C-terminal (His)6-tag and a
tobacco etch virus (TEV) protease cleavage site to facilitate protein
purification and tag-cleavage, respectively. A pNatB expression
vector, encoding subunits Naa20 and Naa25 of the fission yeast
NatB acetylation complex40 was obtained from Addgene (plasmid
ID: 53613).
Protein expression and purification
Protein domains APP E2 and E2-qm were expressed with N-
terminal acetylation to mimic the continuation of the polypep-
tide backbone in the complete APP. To this end, each E2
expression plasmid was transformed into E. coli BL21(DE3)
cells that were co-transfected with an expression vector pNatB
that encodes the two NatB acetylation complex subunits (Naa20
and Naa25). This allows endogenous N-terminal acetylation of a
target protein during expression.40 Transformed cells were
grown in 2YT medium containing ampicillin (100 mg L1)
and chloramphenicol (34 mg L1) in shaking flasks at 37 1C
until growth media reached an ODB 1. Protein expression was
induced by addition of IPTG (0.4 mM) with overnight agitation
at room temperature and cells were harvested by low-speed
centrifugation at 4 1C. The clarified cell lysate was prepared in
buﬀer A (20 mM sodium phosphate, pH 7.4, 500 mM NaCl,
5 mM PMSF) and loaded directly onto a pre-equilibrated IMAC
(Ni-NTA) resin. His-tagged proteins were eluted in buﬀer A with
imidazole (250 mM), incubated with TEV protease (in approx
1 : 100 ratio) for 24–48 hours at 4 1C, and buffer-exchanged (to
20 mM imidazole in buffer A) by dialysis. The solution was
reapplied to a Ni-NTA resin for removal of uncleaved protein
and (His-tagged) TEV protease. The fully-cleaved protein was
incubated with EDTA (Z2  excess of protein concentration) to
remove any contaminating metal ions, before final purification
by size-exclusion chromatography on a Superdex-75 gel filtra-
tion column (HR 10/300, Pharmacia) in Mops buffer (20 mM,
pH 7.4, 150 mM NaCl). Purified fractions were pooled, con-
centrated using centrifugal filters and stored at 80 1C.
Two control proteins, APP D2 domain (encompassing APP695
residues 133–189; see Fig. 2a and b) and human copper
chaperone Atox1 were also expressed and purified from Pichia
pastoris and E. coli hosts, respectively, as previously reported.4,41
Protein concentrations were estimated based on solution absor-
bance at 280 nm using molar extinction coefficients calculated
from their respective amino acid compositions: e(280) =
15930 cm1 M1 for APP E2 (after TEV-cleavage); 7365 cm1 M1
for APP D2; 2980 cm1 M1 for Atox1.
Spectroscopic methods
UV-visible spectra were recorded on a Varian Cary 300 spectro-
photometer in dual beam mode with quartz cuvettes of 1.0 cm
path length. All titrations with metal ions were performed in
appropriate buﬀers and corrected for baseline. Circular dichroism
(CD) spectra were recorded on a Chirascan-plus spectrometer
(Applied Photophysics) using a quartz cell (0.1 cm). Spectra were
averaged from three scans.
Quantification of Cu(I) binding
Quantification of Cu(I) binding was conducted by competition
with probe ligand L based on eqn (4) and (5) with eqn (6)
derived from them via the mass balance for each competing
component (charges omitted in eqn (4)–(6) for clarity). Eqn (6)
was employed for curve-fitting of the experimental data to
derive the conditional dissociation constant KD of Cu
IP.
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The fitting was based on the known total concentrations of
[Cu(I)]tot, [L]tot and [P]tot and the experimental equilibrium
concentration of [CuIL2]
3 that was determined under each
condition from the characteristic solution absorbance of the
complex (Table 1).16
CuIL2+ P" Cu
IP + 2L (4)
Keq ¼
CuIP
 ½L2
CuIL2½ ½P ¼
1
KDb2
(5)
P½ tot
CuI½ tot
¼ 1 ½Cu
IL2
CuI½ tot
þ KDb2
L½ tot
½CuIL2  2
 2
CuIL2
 
1 Cu
IL2
 
CuI½ tot
 
(6)
The spread of the b2 values for diﬀerent probe complexes
[CuIL2]
3 (Table 1) mean that, by varying the identity and
relative concentration of the selected probe ligand, the free
Cu+ concentration (expressed as pCu+ = log[Cuaq+]) can be
buﬀered anywhere in the range 9 o pCu+ o 19. Conse-
quently, reaction 4 may be tuned to be non-competitive for
estimation of the stoichiometry of Cu(I) binding to the protein
or to be competitive for determination of KD.
1,16 In the former
case, the target metal site in protein P removes Cu(I) quantita-
tively from [CuIL2]
3. In the latter case, the target metal site in
protein P competes for Cu(I) eﬀectively with metal fraction
being controlled within a range of 20–80% of total Cu(I) content
for sensitive and reliable estimation.
The experiments were conducted in deoxygenated buﬀers
containing reductants NH2OH and/or Asc in an anaerobic
glovebox ([O2] o 1 ppm) according to reported protocols.4,16
Briefly, a set of solutions were prepared that contained identical
total concentrations of Cu(I) (produced in situ from reduction of
CuSO4 by excess NH2OH/Asc) and a probe ligand L, but varying
total concentrations of the target protein P. The equilibrium
concentrations of the probe complex [CuIL2]
3 were determined
for each set of solutions from their stable spectra and were fitted
to eqn (6) to derive an average KD for the Cu
IP complex.
Ternary complex isolation
Samples of reaction mixtures (B1.0 mL) were applied to a
desalting gel filtration column (Econo-Pac 10DG packed with
P6-DG gel, Bio-Rad) equilibrated inMops buﬀer (pH 7.4, 100mM
NaCl). Continued addition of buﬀer induced gravity flow
through the resin. Elution fractions (1.0 mL) were collected
and the UV-visible absorbance spectrum of each was recorded.
Mass spectrometry
Intact protein masses (for denatured proteins) were acquired
on an Agilent 6220 ESI-TOF LC/MS mass spectrometer coupled
to an Agilent 1200 LC system (Agilent, Palo Alto, CA) and
reference mass corrected via a dual-spray electrospray ionisa-
tion (ESI) source. Acquisition was performed using the Agilent
Mass Hunter Acquisition software version B.02.01 (B2116.30)
and analysed using Mass Hunter version B.05.00 (B5.0.519.0).
Mass spectrometer conditions: ionisation mode: electrospray
ionisation; drying gas flow: 7 L min1; nebuliser: 35 psi; drying
gas temperature: 325 1C; capillary voltage (Vcap): 4000 V; frag-
mentor: 250 V; skimmer: 65 V; OCT RFV: 250 V; scan range
acquired: 100–3200 m/z; internal reference ions: Positive ion
mode: m/z = 121.050873 and 922.009798. Protein samples were
desalted prior to MS analysis using a reverse phase Aeris 3.6 mm
WIDEPORE XB-C18 150  2.1 mm column (Phenomenex) and a
linear acetonitrile elution gradient (5–95% v/v; 0.1% formic
acid) over 10 min at 0.2 mL min1.
Native MS spectra were acquired on a Synapt HDMS system
(Waters, Manchester, U.K.), using nanoESI in the positive ion
mode. Instrument settings: capillary voltage, 1.7 kV; cone
voltage, 60 V; trap collision energy, 40 V; source temperature,
50 1C. Prior to analysis, protein samples were buﬀer-exchanged
into 10 mM ammonium acetate (pH 7.4) using centrifugal filters.
Results
Expression, purification and characterization of APP E2
domains
The APP E2 domain and a quadruple variant E2-qm (in which
the four His residues of the M1 site were mutated to Ala; see
Fig. 2a and c) were expressed and isolated from E. coli cells with
N-terminal acetylation (see Experimental section). Protein
purity was confirmed by SDS-PAGE (Fig. S1, ESI†) and identity by
ESI-MS (Table S2, ESI†). The proteins emerged with the same
elution volume from an analytical size exclusion column at a
position consistent with the monomeric form (Fig. S2a, ESI†).
Circular dichroism (CD) experiments were consistent with the
a-helical structure persisting in solution (Fig. 2c and Fig. S2b, ESI†).
Samples of APP D2 (Fig. 2b) and the copper metallo-chaperone
Atox1 were expressed and isolated as reported.4,26 They were used
as controls for Cu(I) binding experiments of APP E2.
APP E2 distorts the solution spectra of [CuIL2]
3
Titration of APP E2 into a solution of [CuI(Fz)2]
3 in Mops buﬀer
at pH 7.4 led to changes in the absorption envelope (Fig. 3b versus
Fig. 3a). Similar changes were detected for equivalent experiments
with [CuI(Bca)2]
3, [CuI(Fs)2]
3 and [CuI(Bcs)2]
3 (Fig. 4a and
Fig. S3a, b, S4a, b, ESI†), suggesting formation of a Cu(I)-mediated
ternary complex E2–Cu(I)–L in each case (such as eqn (7); charges
omitted for clarity):
CuIL2 + E2- E2–Cu(I)–L + L (7)
Notably, upon titration with APP E2, the positions of absor-
bance maxima for [CuI(Bca)2]
3 and [CuI(Bcs)2]
3 in the visible
region appeared to remain unchanged, but two tight isosbestic
points at 405 and 455 nm for the former and one at 385 nm for
the latter were detected (Fig. 4a and Fig. S4, ESI†), suggesting a
clean reaction (such as eqn (7)) in these two cases.
Intriguingly, upon addition of one equiv. of heparin (relative
to APP E2) into each of the above solutions, the solution spectra
were restored to the fingerprints for the complex anions
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[CuIL2]
3 (Fig. 3c, 4b and Fig. S3c, S4c, ESI†). For the Bcs
system, even the original spectral intensity in the absence of
APP-E2 was restored (Fig. S4c, ESI†). This suggests that heparin
may have modified APP E2 to allow competition for Cu(I)
binding with each of the four probe ligands according to
eqn (4)–(6) and that the affinity of Bcs for Cu(I) is too strong
to allow APP E2/heparin to compete.
Heparin is a physiological partner of APP and known to
interact with and bind to the E2 domain specifically.32–35
Addition of heparin into each of the [CuIL2]
3 probe solutions
caused no change to the solution spectra (Fig. 3a, 4 and
Fig. S3a, S4a, ESI†), indicating that heparin itself cannot extract
Cu(I) from these probe complexes, nor interact with these
probes via a Cu(I)-bridge.
Further controls were conducted with the APP D2 domain
(that has been referred to as the ‘copper binding domain’
CuBD; Fig. 2b). Its Cu(I) binding aﬃnity has been determined
to be logKD =10.1 at pH 7.0.26 As observed previously, addition
of APP D2 into solutions containing complex [CuI(Fz)2]
3 or
[CuI(Fs)2]
3 decreased the spectral intensities but did not distort
the spectral envelope (see Fig. 3d and Fig. S3d, ESI†), consistent
with the competition reaction according to eqn (4). Addition of
heparin into both systems induced no further change to
their spectra (Fig. 3d and Fig. S3d, ESI†). It is apparent that
heparin does not alter the aﬃnity of Cu(I) binding to the APP D2
domain.
It was noted that the absorbance maxima of both
[CuI(Bca)2]
3 and [CuI(Bcs)2]
3 in the visible region are indis-
tinguishable from those of their putative ternary complexes
E2–Cu(I)–L (L = Bca or Bcs) (see Fig. 4 and Fig. S4, ESI†). This
may give a misleading impression of no ternary complex
formation. An additional experiment is necessary to test for
ternary complex formation. Fig. 5 for L = Bca shows a titration
of Cu(I) into a solution containing both APP E2 and ligand L
with a control titration of the ligand L only. Titration of Bca
(100 mM) with Cu(I) generated a titration curve with a sharp
turning point, as expected, at [Cu]tot : [Bca]tot = 0.5 : 1 (Fig. 5a).
An equivalent titration in the presence of APP E2 (30 mM)
generated an apparent endpoint at [Cu]tot : [Bca]tot B 0.67 : 1
but with an absorbance intensity at 562 nm of onlyB70% that
of the control (compare Fig. 5b versus Fig. 5a). In contrast, the
same experiments with further addition of one equiv. of
heparin relative to APP E2 led to a titration curve with an
apparent endpoint at [Cu]tot : [Bca]tot B 0.85 : 1 and a full
absorbance intensity at 562 nm of that of the control (Fig. 5c
versus Fig. 5a). These experiments indicated that, at each Cu(I)
saturation titration point, quantitative formation of the probe
complex [CuI(Bca)2]
3 was prevented in the absence of heparin
but occurred in the presence of heparin. The poorly-defined
titration endpoint in Fig. 5c indicated that the APP E2/heparin
complex competes weakly with ligand Bca for Cu(I). This is also
the case for the system of Bcs (Fig. S4, ESI†).
These experiments demonstrate that: (i) APP E2 forms a
stable ternary complex with each of the four probe ligands,
mediated by Cu(I) via eqn (7); (ii) heparin disrupts the ternary
complexes, enabling an eﬀective competition for Cu(I) between
APP E2 and each ligand L according to eqn (4); (iii) heparin
itself has no detectable aﬃnity for Cu(I). These conclusions
were consolidated by further experiments.
Fig. 3 Changes in solution spectrum of [CuI(Fz)2]
3 under diﬀerent con-
ditions: (a) bona fide [CuI(Fz)2]
3 (composition: [Cu]tot, 55 mM; [Fz]tot,
140 mM; [NH2OH]tot, 1.0 mM, [Mops] 50 mM; pH 7.4); (b) after addition
of APP E2 (20 mM) into (a); (c) after addition of APP E2 and heparin H3393
(each 20 mM) into (a); (d) upon addition of APP D2 (50 mM) into (a). Addition
of heparin H3393 (20 mM) only into (a) or (d) did not alter the spectra.
Fig. 4 Solution spectra for a series of solutions containing [CuI(Bca)2]
3
([Cu]tot, 36 mM; [Bca]tot, 82 mM; [NH2OH]tot, 1.0 mM) and increasing
quantities of APP E2 (0–50 mM) in Mops buffer (50 mM, pH 7.4) in the
absence (a) and presence (b) of one equivalent of heparin H3393 (relative
to APP E2). Note: the spectral changes with isosbestic points at 405 and
455 nm were observed for (a), but not for (b).
Fig. 5 Change in A562 upon titration of Cu
I into Bca (100 mM) solution
containing (a) no APP E2; (b) APP E2 (30 mM); (c) APP E2 and heparin H3393
(each 30 mM). Titrations were conducted in Mops buﬀer (50 mM, pH 7.4,
NaCl, 100 mM; NH2OH, 1.0 mM).
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Formation of stable ternary complexes invalidates
quantification of metal binding aﬃnity
Quantification of Cu(I) binding to APP E2 was hampered by the
formation of a stable ternary complex with each of the four
probe ligands, but the diﬃculty was lifted upon addition of
heparin that disrupts these ternary complexes. The low aﬃnity
probe ligand Fs competes weakly for Cu(I) with the E2/heparin
complex‡ and was employed to determine the Cu(I) binding
stoichiometry of the complex under non-competitive condi-
tions. Titration of the E2/heparin complex into a solution of
[CuI(Fs)2]
3 ([Cu]tot, 30 mM; [Fs]tot, 70 mM) led to an initial linear
decrease of the [CuI(Fs)2]
3 concentration with an extrapolated
intercept at [E2]tot : [Cu]tot = 0.33 (Fig. 6a(i)), consistent with a
binding stoichiometry of Cu(I) : E2 = 3 : 1 under these condi-
tions. Control experiments with variant APP E2-qm provided
[E2]tot : [Cu]tot = 0.50 under the same conditions (Fig. 6a(ii)).
Consequently, it is concluded that a single equiv. of Cu(I) binds
at the M1 site that features four His ligands (Fig. 2c).
Systematic testing showed that the APP E2/heparin complex
competed for Cu(I) eﬀectively with ligand Fz according to
eqn (4) but that the complex with APP E2-qm competed only
weakly under the same conditions (Fig. 6b(i) vs. Fig. 6b(ii)). This
is consistent with the highest aﬃnity being associated with the
M1 site. The experimental data in Fig. 6b(i) fitted satisfactorily
to eqn (6) to yield logKD = 11.9 for the M1 site at pH 7.4.
Ligand Bca competed more strongly for Cu(I) with the APP
E2/heparin complex and equivalent experiments with Bca esti-
mated logKD = 12.2 for the M1 site (Fig. 7a(i)). New data
acquired from a 1 : 1 dilution of each analytical solution
(Fig. 7a(ii)) provided an identical estimate of the logKD value.
Note that the dilution did not simply halve the absorbance
values (solid black versus dotted red dashed traces) but induced
a lower concentration of [CuI(Bca)2]
3 and a higher concen-
tration of [Cu(I)–E2] to maintain the relationship of eqn (5) (as
required by Le Chatelier’s principle). In fact, the derived Cu(I)
affinity for the E2/heparin complex was not altered within the
experimental error (logKD = 12.1  0.2, see Table 2) upon
systematic variation of the concentration of each competing
component and/or upon swapping competing ligands with
close affinities (i.e., Fz for Bca).
This confirms that the His-rich M1 site in E2/heparin
provides a single Cu(I) binding site of picomolar aﬃnity. A
structural study of metal ion binding to the M1 site (via soaking
of apo-E2 crystals) documented CuII(His)4 (Fig. 2c) and Zn
II(His)3
sites.25 A further mutation study demonstrated that stable bind-
ing of Cu(II) by the M1 site requires coordination by all four His
ligands, but only a sub-set of 2–3 for Zn(II).36 As heparin itself
shows no detectable affinity for Cu(I), it is unlikely that the
glycosaminoglycan is directly involved in the Cu(I) binding.
However, in the absence of heparin, equivalent experiments
and data analysis generated misleading logKD values. These
were scattered over four orders of magnitude when the con-
centrations of the species in eqn (4) were varied and/or the
competing ligand was swapped (Table 2). The scattering is
symptomatic of the formation of ternary complexes, according
to eqn (7). This disobeys the assumptions of eqn (4) and
invalidates the estimations. Note that a 1 : 1 dilution of the test
solutions of Fig. 7b(i) simply halved the absorbance of each
solution without shifting the binding equilibrium, as required
by eqn (4) (compare behaviour of Fig. 7a(i and ii)). These
observations are consistent with the presence of ternary
Fig. 6 Characterization of Cu(I) binding to APP E2 in the presence of
heparin. (a) Quantification of Cu(I) binding stoichiometries of APP E2 (i) and
its mutant APP E2-qm (ii) under non-competitive condition with probe
[CuI(Fs)2]
3 (composition: [Cu]tot = 30 mM, [Fs]tot = 70 mM). (b) Quantifica-
tion of Cu(I) binding aﬃnity with probe [CuI(Fz)2]
3 (composition: [Cu]tot =
50 mM, [Fz]tot = 300 mM) under competitive conditions for APP E2 (ii) with
non-competitive control of APP E2-qm (i). The best curve fitting of the
experimental data set (i) to eqn (6) (shown in solid trace) provided a
logKD = 11.9 for the Cu(I) binding aﬃnity of the M1 site in APP E2. All
experiments were conducted in Mops buﬀer (50 mM, pH 7.4) with added
reductants (1.0 mM NH2OH and 0.5 mM Asc).
Fig. 7 Quantification of Cu(I) binding aﬃnities of APP E2 with probe
[CuI(Bca)2]
3 (compositions: [Cu]tot = 36 mM, [Bca]tot = 82 mM) in the
presence (a) or absence (b) of heparin H3393 (1.0 equiv. relative to E2). The
experimental data set (ii) in empty circles were obtained by a 1 : 1 dilution of
each solution for the data set (i). The best curve fittings of the experimental
data sets (i and ii) to eqn (6) (shown in two solid traces) derived a consistent
logKD = 12.2 for the highest Cu(I) binding aﬃnity for E2/heparin complex
in (a), but inconsistent logKD (=13.4 and 13.1, respectively) for APP E2
domain in (b). The dashed traces in (ii) are the simple 1 : 1 dilution curve of
data sets (i). All experiments were conducted in Mops buﬀer (50 mM,
pH 7.4) with added reductant (1.0 mM NH2OH).
‡ It has been suggested that long-chain heparins, such as the preparation used in
this study (H3393, 19 kDa), may form dimeric (E2)2–heparin complexes. However,
detailed studies by Hoefgen et al. indicated that this was due to two E2 domains
independently binding at distant ends of the same (long) heparin chain, rather
than stabilising a dimeric E2–E2 interface (see ref. 30). Accordingly, in the
quantitative copper-binding analysis presented here, each E2 molecule is treated
as an independent Cu(I)-binding moiety. As the exact molecular nature of the
structure has not been elucidated, the complex is referred to as ‘E2/heparin’
herein.
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complexes: note that the equilibrium of eqn (7) is unaﬀected by
dilution.
The above experiments demonstrate that: (i) an eﬀective
ligand competition between a protein P and a ligand L for a
metal ion M described by eqn (4) must satisfy eqn (6) with
consistent estimates of the constants KDb2 upon variation of
the concentrations of each competing component and/or upon
change of the competing ligands of overlapping aﬃnities;
(ii) dilution of a set of competing solutions provides a simple
diagnostic evaluation of whether the equilibrium of eqn (4)
holds for the system; (iii) in the presence of heparin, the M1 site
in APP E2 possesses picomolar aﬃnity for Cu(I).
Isolation and characterization of the stable E2–Cu(I)–Bca
ternary complex
Formation of the ternary complex(es) involving ligand Bca was
investigated systematically. A series of solutions were prepared
in Mops buﬀer (50 mM; pH 7.4; NaCl, 100 mM) containing
ligand Bca (80 mM) plus APP E2 or a control protein (APP E2-qm,
APP D2 or Atox1; each 30 mM). Cu(I) solution (CuIISO4, 30 mM,
NH2OH, 1.0 mM) and/or heparin (30 mM) were added selectively.
The details are listed in Table 3.
The possibility of stable complex formation in each case was
tested by separation of the reaction mixture on a simple
desalting column (see inset in Fig. 8). Fraction I contained
protein and/or protein complex(es) with molar masses46 kDa
whereas fraction II contained components of small molecules
with molar masses o6 kDa only. Each fraction was character-
ized by comparing its solution spectrum against controls of
each added purified protein, the ligand Bca and a solution
containing [CuI(Bca)2]
3 anions (Fig. 8 and Fig. S5, S6, ESI†).
The results demonstrated: (i) ligand Bca alone cannot form a
detectable complex with APP E2, nor in the presence of Cu(II)
(Fig. 8a and Table 3, expts 1 and 2); (ii) in the presence of Cu(I),
ligand Bca formed a stable (ternary) complex with APP E2 that
can be isolated (Fig. 8c and d; expt 3), but that was disrupted by
heparin (Fig. 8a and b; expt 4); (iii) no Bca-protein complex was
detected with control proteins APP E2-qm (disabled M1 site),
APP D2 or Atox1 under the same conditions as (ii) (Fig. 8a
and b; expts 5–7). The results suggest that the E2-Bca complex
detected and isolated in expt 3 is specific for the APP E2 protein
and is mediated by Cu(I) binding to the M1 site in the protein.
We have demonstrated that all three control proteins bind Cu(I)
with different affinities: logKDB 10 for both APP E2-qm and
APP D2 (see Fig. 6 and ref. 26) and logKD = 17.4 for Atox1
(see ref. 4).
The isolated E2–Cu(I)–Bca complex was chromophoric and
characterized by a full solution spectrum shown in Fig. 8c.
Fingerprints for the presence of Cu(I), Bca and protein are seen
by absorbance at 560, 335 and 280 nm, respectively, although
that at 280 nm for APP E2 is masked by the intense absorbance
of the Bca ligand (Fig. S4, ESI†). On the other hand, the
absorbance intensity at 560 nm for non-protein fraction II from
expt 3 was considerably weaker than those of the equivalent
fraction from expt 4 (compare Fig. 8d versus Fig. 8b), consistent
Table 2 Derived Cu(I) binding aﬃnities for APP E2 by competition with
diﬀerent probe ligands at various conditions in Mops buﬀer (50 mM,
pH 7.4)
Ligand (L)
Components for
Cu(I) competition (mM) logKD for Cu
I–E2a
[Cu]tot [L]tot [E2]tot  heparin + heparin
Bcs 40 100 50 14.8 n/ab
150 14.5 n/ab
Bca 36 82 10 13.0 12.2
50 13.4 12.1
18 41 5 12.8 12.2
25 13.1 12.2
7.2 16.6 4 11.5 11.9
12 11.9 12.0
Fz 50 300 20 11.7 12.0
42.5 11.0 11.9
a Determined in the absence and presence of one equivalent of heparin
(relative to APP E2) and calculated via eqn (6). b The protein aﬃnity is
too weak to be defined under the given experimental conditions.
Table 3 Experiments toward formation of a stable Cu(I)-mediated ternary
complexa
Expt
[Cu(II)]
(mM)
[Bca]
(mM)
[NH2OH]
(mM)
[heparin]
(mM)
Protein
(30 mM)
Ternary
complexb
1 — 80 1.0 — E2 No
2 30 80 — — E2 No
3 30 80 1.0 — E2 Yes
4 30 80 1.0 30 E2 No
5 30 80 1.0 — E2-qm No
6 30 80 1.0 — D2 No
7 30 80 1.0 — Atox1 No
a Conducted in Mops buﬀer (50 mM, pH 7.4, 100 mM NaCl). b Detected
by co-elution of respective protein and ligand Bca from a desalting gel
filtration column.
Fig. 8 Solution spectra of protein fraction I (in solid line) and non-protein
fraction II (in dashed line) separated by a desalting gel-filtration column
(see inset) from the expts listed in Table 3: (a and b) fraction I (a) from expts
1, 2, 4–7 and fraction II (b) from expts 4–6; (c and d) fraction I (c) and
fraction II (d) from expt 3. Absorbance intensity at l o 450 nm and l 4
450 nm is shown on the left and right vertical axes, respectively. The
spectrum (a) is indistinguishable from the spectrum of each purified
protein sample alone.
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with the observation that Cu(I) was trapped by APP E2 as a
ternary complex in expt 3 only. All these observations support
the above model of formation of a Cu(I)-mediated ternary
complex.
Further support and characterization are provided by native
ESI-MS analysis (Fig. 9 and Table S3, ESI†). Addition of one
equiv. of CuIISO4 into apo-E2 in volatile ammonium acetate
buﬀer (10 mM, pHB 7) allowed detection of both a 1 : 1 Cu–E2
complex and apo-E2 by native ESI-MS (Fig. 9a and Table S3,
ESI†). Addition of Bca (2 equiv.) led to detection of new protein
components at low relative abundances (Fig. 9b). Further
addition of 5 equiv. of reductant ascorbate (Asc) into the latter
solution increased dramatically the relative abundance of one
peak in each of the charge states (Fig. 9c). The deconvoluted
masses corresponding to those peaks was 25 833 (3) Da,
consistent with the theoretical mass of 25 834 Da for the ternary
complex E2 : Cu(I) : Bca = 1 : 1 : 1. These experiments identify the
stoichiometry of the stable ternary complex as E2–Cu(I)–Bca
and confirm the existence of eqn (7).
Discussion
Nature of the APP E2 ternary complexes and their biological
implications
This work demonstrated that Cu(I) mediates formation of
stable ternary complexes between the APP E2 domain and a
set of bidentate ligands (Bcs, Bca, Fz and Fs; Fig. 1). A
systematic study of the representative ligand Bca showed that:
(i) formation of such ternary complexes is specific for the APP
E2 domain and is dependent on Cu(I), but not Cu(II), binding to
the M1 site in E2; (ii) the composition of the ternary complex
with ligand Bca is E2 : Cu(I) : Bca = 1 : 1 : 1 as, presumably, is the
case for the other ligands; (iii) the ternary complexes are
disrupted readily by heparin, a partner that interacts physiolo-
gically with APP.
The APP E2 domain features a tetra-His M1 metal binding
site (Fig. 2c) which, in conjunction with several nearby basic
residues, forms a positively charged surface patch.25 APP E2
and homologues bind heparins (a class of negatively charged
polysaccharide molecules of varying length) via interaction
with these basic residues.32–35 Metal binding to the M1 site
enhances the binding affinity of APP E2 for heparin.36 These
previous observations may help to understand the specificity of
APP E2 in forming stable Cu(I)-mediated ternary complexes with
the Cu(I) probe ligands that can be disrupted by heparin. Each
ligand (Fig. 1) carries two negative charges and may interact
electrostatically with the positively charged residues surrounding
the M1 site. A shared coordination of Cu(I) between the M1 site
and the probe ligand L may enhance such interactions to allow
formation of a stable 1 : 1 : 1 ternary complex. There are several
lines of evidence supporting this model:
(i) Control proteins such as APP D2, Atox1 and many other
Cu(I) binding proteins bind Cu(I) with diﬀerent aﬃnities, but
they do not form ternary complexes with the Cu(I) probe ligands
of Fig. 1 (expts 6 and 7, Table 3). In fact, APP E2 is the first
example of a protein forming a stable Cu(I)-mediated ternary
complex.
(ii) Variant APP E2-qm lacks a functional M1 site but can still
bind two equiv. of Cu(I) weakly. However, such binding does
not promote formation of a ternary complex (Table 3, expt 5),
demonstrating that Cu(I) binding to the M1 site is essential.
(iii) A previous study demonstrated that the M1 site can also
bind Cu(II) and Zn(II), but the stable binding of Cu(II) is
conditional upon the presence of an intact M1 site with all
four His sidechains acting as ligands (Fig. 2c).36 In contrast,
stable binding of Zn(II) does not require an intact M1 site and
exhibits a need for 2–3 His ligands from the M1 site.36 Cu(I) has
the same d10 electronic configuration as Zn(II) and is even more
flexible with its coordination number (2–5) and geometry.
Consequently, while stable Cu(II) binding by the M1 site cannot
be shared by an external ligand and thus cannot promote
ternary complex formation, the flexibility of Cu(I) binding to
the M1 site apparently allows sharing of the Cu(I) coordination
by an external ligand L and formation of the stable ternary
complexes.
(iv) Heparins constitute a group of highly negatively charged
molecules of varying sizes that have been demonstrated to
interact with and bind to E2 and E2-like proteins via interaction
with a group of basic residues located close to the M1 site.
Heparin appears to disrupt weak interactions between E2 and
ligand molecules L. This apparently allows Cu(I) to bind to the
M1 site with picomolar aﬃnity.
Formation of the Cu(I)-mediated ternary complexes observed
in this work may be an anomaly specific to the in vitro experi-
ments. However, the APP E2 domain and, in particular, the
region involving the M1 site has been demonstrated to be an
important site of interaction with both metal ions and other
components of the extracellular matrix.22,23 Accumulating
evidence suggests that these interactions are important for
Fig. 9 Analysis of interactions between APP E2, Cu and Bca under various
conditions by native ESI-MS (left pane: full spectra; right panel: close-up
view of the peaks for 10+ and 11+ charge states): (a) apo APP E2 and
CuIISO4 in 1 : 1 molar ratio; (b) addition of Bca (2 equiv.) into sample (a);
(c) addition of reductant Asc (5 equiv.) into sample (b). All samples were
prepared in ammonium acetate buﬀer (10 mM, pH B 7) and spectra
acquired using identical machine settings (see Experimental section for
details).
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the physiological functions of APP and its homologues APLP1
and APLP2.22,23,42 This work demonstrates that APP E2 is able
to interact, via formation of ternary complexes, with each of the
four Cu(I) ligands shown in Fig. 1 whose aﬃnities for Cu(I) span
a range over six orders of magnitude (Table 1).
It is interesting to speculate that similar metal-bridged
interactions involving biological co-ligand(s) may exist in vivo,
and may be dependent on specific metal ions, such as Cu(I).
Furthermore, this work suggests that ternary interactions could
be regulated by biological co-ligand(s) and by heparin: these
ligands could promote copper transfer to and/or from the M1
site, thereby facilitating diverse physiological functions.23,42
Such interactions may be significant in modulating the func-
tions of APP at synapses where high concentrations of copper
are reportedly released.43–45 In addition, APP and the HSPG
glypican-1 (Gpc-1) co-localise in intracellular compartments46
and Cu-APP complexes are thought to play a role in the degrada-
tion of Gpc-1 heparan sulfate chains in endosomes.47 The
interesting interplay between Cu(I)-binding, heparin-binding
and ternary complex formation could be important factors
influencing APP function and Alzheimer disease pathogenesis –
a possibility that remains to be explored in future research.
A lesson for conditions of reliable quantification of metal-
binding aﬃnity by ligand competition
Metal binding aﬃnities in proteins frequently reach nanomolar
concentration or below and can only be assessed reliably via
ligand competition at the present time, regardless of the detec-
tion readouts (absorbance, fluorescence, NMR, EPR, isothermal
titration calorimetry (ITC) or enzyme activity).1,48 Reliable quan-
tification requires an eﬀective competition (as described by
eqn (2)) that must satisfy the metal speciation analysis at
equilibrium by eqn (3) or, more specifically, by eqn (4)–(6) for
the Cu(I) probes employed in this work. Although the transfer of
metal ions between the competing partners is usually mediated
via formation of transient ternary complexes, this study docu-
mented that the formation of stable ternary complexes violates
the conditions of eqn (2)–(6) and invalidates subsequent affinity
determination.
A set of useful diagnostic experiments was documented for
detection of the formation of stable ternary complexes. These
include:-
(i) Close examination of the fingerprints of the selected
detection probe (including but not limited to the solution
spectrum) to ensure that they are not altered by the ligand
competition (e.g., Fig. 3, 4 and Fig. S3, S4, ESI†);
(ii) For an absorbance probe, conducting control metal ion
titrations of the probe ligand in the absence and presence of
the target protein. Inconsistent metal-probe complex recovery
at the saturating metal titration point indicates the possibility
of formation of stable ternary complex(es) (e.g., Fig. 5);
(iii) Confirmation of the binding equilibrium of eqn (2) by
variation of the concentrations of each individual competing
component and/or by observation of a simple ‘dilution eﬀect’.
Aﬃnity data invariant with these changes indicates negligible
(if any) ternary eﬀects (e.g., Fig. 6, 7 and Table 2).
(iv) Employment of alternate competing ligands with over-
lapping aﬃnity ranges. Invariant estimates documents relia-
bility, provided that a unified aﬃnity scale is used (see Table 2).
It is anticipated that formation of ternary complexes may
alter the spectroscopic properties of a given probe. However,
this may not be obvious in certain cases such as those shown in
Fig. 4 and Fig. S4 (ESI†) for ligand L = Bca, Bcs. Then the
experiments of (ii) and (iii) above become important. Dilution
controls are a simple but eﬀective mean of verifying the
integrity of the equilibrium for a 1 : 2 competition such as
eqn (4). Dilution with buﬀer will shift the binding equilibrium
to a new position, without aﬀecting determination of the metal
aﬃnity. Such controls have been conducted for characteriza-
tion of many Cu(I)-binding protein targets previously and
confirm the reliability of these data.16,26,49–51
Where possible, aﬃnity estimates should also be conducted
with at least two independent competing standards with over-
lapping aﬃnity ranges. This is possible when both probes
impose appropriate free metal buﬀering conditions for a given
target.16 This is demonstrated for the APP E2/heparin complex
in this work: in the presence of heparin, a consistent Cu(I) KD of
picomolar aﬃnity was determined for the M1 site in E2 using
two independent probe ligands Fz and Bca (Table 2). The Cu(I)
aﬃnity of ligand Fs is too weak while that of Bcs is too strong
for this purpose (Fig. 6a and Fig. S4, ESI†).
Conclusions
This work documents the formation of stable Cu(I)-mediated
ternary complexes between the APP E2 protein domain and
each of four Cu(I)-responsive probe ligands (Fs, Fz, Bca and
Bcs). This is the first reported example of a stable ternary
complex involving these commonly used probe ligands and
provides a convenient ‘negative control’ since unreliable KD
values are extracted under the conditions of ternary complex
formation. Several simple diagnostic control experiments are
recommended to probe the presence of stable ternary complexes
in metal-binding competition experiments. Utilizing these criteria,
we demonstrated that ternary complexes are precluded when APP
E2 is bound to its biological ligand heparin. Competition experi-
ments provided reliable estimates of a picomolar aﬃnity for the
His-rich M1 site in APP E2/heparin complex. This work allows new
insights into a potential regulation of APP functions regulated by
copper binding and heparin interaction.
Abbreviations
APP D2 Amyloid precursor protein D2 domain
APP E2 Amyloid precursor protein E2 domain
APLP1 Amyloid precursor-like protein 1
APLP2 Amyloid precursor-like protein 2
Asc Ascorbate
Bca Bicinchoninic anion
Bcs Bathocupro¨ine disulfonate
eq Equation
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equiv. Equivalent(s)
ESI-MS Electrospray ionization mass spectrometry
Fs Ferene S
Fz Ferrozine
GAG Glycosaminoglycan
HSPGs Heparan sulfate proteoglycans
His Histidine
Mops 3-(N-Morpholino)propanesulfonic acid
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